Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian Cancer

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian Cancer


In order to request this CME/CE activity for your center, please contact Samantha Miller at Smiller@gotoper.com or call (609) 325-4808
 

Oncology Best Practice™:
Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian Cancer
August 2017 - December 2017

Overview:

The development of new clinical treatment options that can improve outcomes for patients with ovarian cancer is a major focus of clinical research. Several options that target the poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) family are in different stages of development/approval. This family comprises 17 enzymes that play an important role in numerous cellular functions, including DNA transcription and repair, genomic stability maintenance, cell cycle regulation, cell signaling, and cell death. [Anwar, 2015; Benafif and Hall, 2015] d DNA. PARP inhibition may keep tumor cells from repairing their DNA, leading to their death. Several PARP inhibitors have demonstrated efficacy in the treatment of patients with ovarian cancer in clinical trials, and this class of medications has begun to make the transition from laboratory investigation to clinical application. FDA approval has been granted for two agents, with several others in late clinical development in 2017, altering the treatment landscape.

There are major educational gaps related to the medical management of ovarian cancer in community practice settings. Knowledge and competence gaps need to be bridged to ensure that optimized outcomes demonstrated in clinical trials are translated to community practices where most of these patients are managed. In order to ensure that state-of-the-art practices are maintained at the point of care outside of clinical trial settings, it is critical to target education to physicians who are key to decision-making concerning medical therapies for ovarian cancer. This will be particularly true in 2017 as many late-stage compounds in clinical trials are poised to enter a field in which educational gaps already exist.

This activity will bring key clinical experts in the medical management of ovarian cancer directly into institutions with identified educational need for an in-depth discussion with healthcare teams on how to optimize sequencing treatment strategies and manage adverse events based on the current evidence in ovarian cancer. The theme of this program will be a practical case-based approach that incorporates recent practice-changing trial data and places these findings in the context of real-world clinical situations that allows for clinical decision-making in multidisciplinary settings. Importantly, small group settings held in the collegial atmosphere of Grand Rounds/Tumor Boards allows for open, fluid interaction with key opinion leaders to get their most pressing patient issues addressed. Indeed, the patient will remain the focus of this activity via practical assessments of how specific characteristics impact thought processes in the clinic, and how quality measures that will be used for reimbursement can be addressed via the use of evidence-based guidelines. All of these important issues require careful assessment to optimize care, and also to inform decisions related to sequencing and switching.

Target Audience

This activity is directed toward medical, surgical and radiation oncologists who treat or manage patients with ovarian cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Describe how PARP inhibition strategies have been applied to the management of recurrent ovarian cancer
  • Discuss how care can be personalized via the use of testing strategies in BRCA-mutant and non-BRCA-mutant patient populations with ovarian cancer
  • Examine PARP inhibitor mechanisms in the context of treatment resistance and emerging role in the maintenance setting
  • Describe effective strategies to proactively plan for and manage treatment-related toxicities in the setting of ovarian cancer

Chair:

Michael Birrer, MD, PhD
Professor, Medicine, Harvard Medical School
Physician, Massachusetts General Hospital
Director, Gillette Center for Gynecologic Oncology,
Massachusetts General Hospital
Boston, MA


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
2728293031
Filter By